Phosphorylation at \(Ser^{26}\) in the ATP-Binding Site of \(Ca^{2+}\)/Calmodulin-Dependent Kinase II as a Mechanism for Switching off the Kinase Activity by Yilmaz, Mehtap et al.
 
Phosphorylation at \(Ser^{26}\) in the ATP-Binding Site of
\(Ca^{2+}\)/Calmodulin-Dependent Kinase II as a Mechanism for
Switching off the Kinase Activity
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Yilmaz, Mehtap, Samudra Saurabh Gangopadhyay, Paul Clifton
Leavis, Zenon Grabarek, and Kathleen G. Morgan. 2013.
Phosphorylation at \(Ser^{26}\) in the ATP-binding site of
\(Ca^{2+}\)/calmodulin-dependent kinase II as a mechanism for
switching off the kinase activity. Bioscience Reports 33(2):
e00024.
Published Version doi:10.1042/BSR20120116
Accessed February 19, 2015 11:58:40 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10646382
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAABiosci. Rep. (2013) / 33 / art:e00024 / doi 10.1042/BSR20120116
Phosphorylation at Ser26 in the ATP-binding site
of Ca2+/calmodulin-dependent kinase II as a
mechanism for switching off the kinase activity
Mehtap YILMAZ*, Samudra S. GANGOPADHYAY†‡, Paul LEAVIS§, Zenon GRABAREK§ and
Kathleen G. MORGAN*1
*Department of Health Sciences, Boston University, 635 Commonwealth Avenue, Boston, MA 02215, U.S.A., †Children’s Hospital Boston,
300 Longwood Avenue, Boston, MA 02115, U.S.A., ‡Department of Surgery, Harvard Medical School, Boston, MA 02215, U.S.A., and
§Boston Biomedical Research Institute, 64 Grove Street, Watertown, MA 02472, U.S.A.
Synopsis
CaMKII (Ca2+/calmodulin-dependent kinase II) is a serine/threonine phosphotransferase that is capable of long-
term retention of activity due to autophosphorylation at a speciﬁc threonine residue within each subunit of its
oligomeric structure. The γ isoform of CaMKII is a signiﬁcant regulator of vascular contractility. Here, we show that
phosphorylation of CaMKII γ at Ser26, a residue located within the ATP-binding site, terminates the sustained activity
of the enzyme. To test the physiological importance of phosphorylation at Ser26, we generated a phosphospeciﬁc
Ser26 antibody and demonstrated an increase in Ser26 phosphorylation upon depolarization and contraction of blood
vessels. To determine if the phosphorylation of Ser26 affects the kinase activity, we mutated Ser26 to alanine or
aspartic acid. The S26D mutation mimicking the phosphorylated state of CaMKII causes a dramatic decrease in Thr287
autophosphorylation levels and greatly reduces the catalytic activity towards an exogenous substrate (autocamtide-3),
whereas the S26A mutation has no effect. These data combined with molecular modelling indicate that a negative
charge at Ser26 of CaMKII γ inhibits the catalytic activity of the enzyme towards its autophosphorylation site at Thr287
most probably by blocking ATP binding. We propose that Ser26 phosphorylation constitutes an important mechanism
for switching off CaMKII activity.
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INTRODUCTION
CaMKII (Ca2+/calmodulin-dependent kinase II) is a ubiquit-
ously expressed serine/threonine protein kinase, which functions
as a multimeric holoenzyme consisting of 12 monomers [1,2].
The holoenzyme is organized into a ring-like structure and the
catalytic/autoregulatorycomponentofeachsubunitisattachedto
thehexamericringbyastalk-likeextension.Twosuchhexameric
rings stacked on top of each other form the dodecameric holoen-
zyme.Theassociationdomainformsthecoreoftheholoenzyme,
whereas the catalytic activity resides in the peripheral ‘foot’-like
structures [1,3].
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Abbreviations used: 2D, two-dimensional; CaM, calmodulin; CaMKII, Ca2+ /calmodulin-dependent kinase II; DMEM, Dulbecco’s modiﬁed Eagle’s medium; DTT, dithiothreitol; FBS,
fetal bovine serum; LC–MS/MS, liquid chromatography tandem MS; PKA, protein kinase A; PSS, physiological saline solution; SCP3, small C-terminal domain phosphatase 3; TCA,
trichloroacetic acid; VSMC, vascular smooth muscle cell; wt, wild-type.
1 To whom correspondence should be addressed (email kmorgan@bu.edu).
Thr287 is the primary site responsible for regulation of the
autonomous activity of CaMKII [4]. Activation of the kinase by
Ca2+/CaM (calmodulin) causes autophosphorylation of Thr287,
whichgeneratesthefullyactiveformofCaMKII.Eachmonomer
is phosphorylated at Thr287 by adjacent CaMKII monomers [5].
Thr287 phosphorylation results in Ca2+-independent activ-
ity of CaMKII that persists upon the removal of Ca2+.
Several other autophosphorylation sites have been described
for CaMKII (Ser26,T h r 254,T h r 262,S e r 280,T h r 305,T h r 306,S e r 319
and Ser350)( [ 6], but see [6a], [7–9]); however, only for some
of them (Thr305,T h r 306 and Thr254) are the functional con-
sequences known [8,10,11]. The most curious of these addi-
tional sites is Ser26 due to its location in the ATP-binding
c   2013 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/
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site. This phosphorylation site is the main focus of the present
work.
Four isoforms of CaMKII are known: α, β, γ and δ [12].
Alternative splicing of these gene products result in multiple
variants[13].Theα andβ isoformshavebeenextensivelystudied
andareexpressedprimarilyinneuronaltissuesandbrain[12,14].
They are reported to play a crucial role in behaviour and memory
through their inﬂuence on LTP (long-term potentiation) at PSDs
(postsynaptic densities) [15].
Unlike α and β isoforms, δ and γ isoforms are, in gen-
eral, ubiquitously expressed [16]. The CAMK2D (encoding δ
CaMKII) gene products have been extensively studied in cardiac
muscle [15–18]. The γ isoform has been studied in the vascu-
lature [11,19–21] and in many other tissue types [12,16,22]. The
δ isoform has been linked with proliferative VSMCs (vascular
smooth muscle cells), whereas the γ isoform appears to be more
closely linked with non-proliferative contractile VSMCs [20,23].
Vascular tone is maintained by the contractility of differentiated
VSMCs. CaMKII has been shown to be a signiﬁcant regulator of
vasculartoneasshownbyexperimentswithantisenseknockdown
of CaMKII and small molecule inhibitors [20,24].
Our group has isolated six CaMKII γ variants, C-1, C-2, G-1,
G-2, B and J, from an aorta smooth muscle cDNA library [19].
The main differences between these variants occur in the seg-
ment that connects the catalytic/regulatory domain with the
association domain. The C-1 and C-2 variants lack variable
region 1 (V1) and variable region 2 (V2). Furthermore, C-2 lacks
an eight amino acid sequence (residues 23–30) that forms part
of the ATP-binding motif of the catalytic domain. Interestingly,
this variant displays defective autophosphorylation at Thr287,
but surprisingly is still able to phosphorylate an exogenous
substrate [19]. Our laboratory has previously reported that this
deleted sequence contains a serine residue (Ser26), as determined
by LC–MS/MS (liquid chromatography tandem MS) of the
recombinant C-1 variant, is autophosphorylated when the kinase
is activated by Ca2+/CaM [7].
Inthepresentpaper,weprovideevidencethatphosphorylation
ofCaMKIIγ atthisnovelautophosphorylationsite,Ser26,occurs
in vascular tissue and is important for the termination of the
sustained activity of CaMKII γ.
EXPERIMENTAL
Tissue preparation
Freshly isolated aorta from the ferret was prepared as previ-
ouslydescribed[11].Stimulatedorunstimulatedaortaringswere
quick-frozen in 5 mM DTT (dithiothreitol) with 10% (w/v) TCA
(trichloroacetic acid) in solid CO2/acetone and stored at −80◦C
for later use. All procedures have been approved by the Bo-
ston University Institutional Animal Care and Use Committee.
The animals were maintained in a manner consistent with the
NIH Guide for the Care and Use of Laboratory Animals and
were obtained and used in compliance with federal, state
and local laws. Physiological experiments were performed us-
ing a PSS (physiological saline solution) as described previously
[20]; 51 mM PSS with 51 mM NaCl replaced by KCl was used
as depolarizing stimulus.
2D (two-dimensional) gels and immunoblotting
SampleswerequickfrozeninasolidCO2/acetoneslurrycontain-
ing DTT and TCA, and washed in acetone with 5 mM DTT. IEF
(isoelectric focusing) tube gels and PAGE gels were prepared as
previously described [19]. Ampholytes used were 3–10 and 5–
6. Gels were transferred on to PVDF membranes and processed
using a standard immunoblotting protocol. Blots were probed
with a total CaMKII γ antibody, a G-2 CaMKII γ antibody and
a vimentin antibody (see the Antibodies and reagents section).
A two-colour LiCor Odyssey (LI-COR Biosciences) instrument
was used to visualize bands quantify densitometric results. Im-
agesshowninFigureswereadjustedidenticallyforeachcomplete
dataset for better visualization (n=3–15) but this did not alter
quantitative values.
Colorimetric dephosphorylation assay
A mixture centaining 50 mM Tris acetate (pH 5.0), 10 mM
MgCl2, 0.5 mM DTT, 10% (v/v) glycerol, 0.1 mM phos-
phopeptides (pSer26,p T h r 254,p T h r 262,p S e r 280,p T h r 287,p S e r 319
and pSer350) was used for the 500 μl reaction with or
without puriﬁed SCP3 (small C-terminal domain phosphatase
3). The peptide sequences used for the experiment are as fol-
lows: pSer26,H 2N-GKGAFS(p)VVRRC-COOH; pThr254,H 2N-
INQMLT(p)INPAK-COOH;pThr262,H 2N-PAKRIT(p)ADQAL-
COOH; pSer280,H 2N-RSTVAS(p)MMHRQ-COOH; pThr287,
H2N-MHRQET(p)VECLR-COOH; pSer319,H 2N-FSAAKS(p)-
LLNKK-COOH;pSer350,H 2N-KGSTES(p)CNTTT-COOH.The
reaction mixture was incubated at 30◦C for 30 min, then 500 μl
of Biomol Green reagent (see the Antibodies and reagents sec-
tion) was added and the samples were incubated for another
30 min at 30◦C. The extent of the reaction was calculated from
the absorbance at 620 nm according to the Biomol Green reagent
protocol.
Antibody generation
Polyclonal antibodies for phosphorylated Ser280 and Ser26 were
generated by immunization of rabbits with the phosphopeptides
CaMKII pSer280 [H2N-RSTVAS(p)MMHRQ-COOH]
and CaMKII pSer26 [H2N-LGKGAFS(p)VVRRCVKKTSTQE-
COOH] These peptides were synthesized as octavalent MAPs
(multipleantigenicpeptides)usingMAPresinfromEMDChem-
icals.ThepeptidesweresynthesizedatBBRI(BostonBiomedical
Research Institute) using an Applied Biosystems Model 433A
Peptide Synthesizer and Fmoc (ﬂuoren-9-ylmethoxycarbonyl)
to protect α-amino groups. Rabbits were immunized with the
peptides following standard procedures at Caprologics.
Cell culture
COS-7 cells were maintained in DMEM (Dulbecco’s modi-
ﬁed Eagle’s medium) culture medium supplemented with 4.5 g/l
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D-glucose, L-glutamine, 110 mg/l sodium pyruvate, 50 units/ml
penicillin, 50 μg/ml streptomycin and 10% (v/v) FBS (fetal
bovine serum). His-tagged CaMKII γ C-1 and mutant cDNAs
in pcDNA4/HisMax TOPO vector were transfected into COS-7
cellsbyusingLipofectamineTM reagent(Invitrogen).Theamount
of LipofectamineTM and the plasmid were titrated for the exper-
iment according to the LipofectamineTM protocol using OPTI-
MEM to increase the transfection efﬁciency. Plasmids were ex-
pressed for 24 h. Cells were lysed on ice with phosphate lysis
buffer(20 mMsodiumphosphate,140 mMNaCl2,3mMMgCl 2,
0.5% Nonidet P40, 1 mM DTT, 1× protease inhibitor mixture
and a standard immunoblotting technique was followed.
Site-directed mutagenesis
C-1 cDNA in pcDNA4/HisMax TOPO was used to mutate Ser26
to alanine (A) or aspartic acid (D) using the primers S26A-sense
5 -GCAAGGGTGCTTTCGCTGTGGTCCGCAGG-3 , S26A-
antisense 5 -CCTGCGGACCACAGCGAAAGCACCCTTGC-
3 , S26D-sense 5 -GGCAAGGGTGCTTTCGATGTGGTCC-
GCAGGTG-3  and S26D-antisense 5 - CACCTGCGGAC-
CACATCGAAAGCACCCTTGCC-3 . QuikChange II XL site-
directed mutagenesis kit was used according to the manufac-
turer’s protocol. Mutations were conﬁrmed later with sequencing
by Euroﬁns MWG Operon.
Dot-blot kinase assay
A solution containing 50 mM Pipes (pH 7.0), 10 mM MgCl2,
10 mM CaCl2, 0.5 μg/ml CaM, 20 μM autocamtide-3 (H2N–
Lys–Lys–Ala–Leu–His–Arg–Gln–Glu–Thr–Val–Asp–Ala–Leu-
COOH), 0.225 mM ATP, 0.1 mg/ml BSA, 1× protease inhibitor
and 5 μl of CaMKII was used in a 50 μl kinase-assay reaction.
The reaction was stopped using 50 mM EDTA. Next, the peptide
was separated from the kinase using 300 kDa cut-off spin
ﬁltration columns. Then 2 μl of the autocamtide-3 fraction of the
assay were spotted onto a nitrocellulose membrane. Dot blots
were blocked and analysed with anti-total phosphothreonine
antibody (see the Antibodies and reagents section). In parallel
experiments under identical conditions, negative controls, con-
sistingeachofnoCaM,noCaMandnoATP,andBSAonly,were
tested with CaMKII wt (wild-type) and resulted in no signal.
Molecular modelling
For modelling the catalytic domain of CaMKII γ C-1 iso-
form, we have used the Swiss Model server (http://swissmodel.
expasy.org/) [25–27]. The model was built using the structure of
PKA (protein kinase) (PDB entry 1ATP) as a template. Residues
12–261 of C-1 were aligned with residues 42–282 of PKA. Re-
buildingofthemissingloopswasdonebytheSwissModelserver.
Co-ordinates for ATP and two Mn2+ ions present in 1ATP were
introduced into the C-1 model and the structure was optimized
with Phenix [28]. Ser26 was either phosphorylated or mutated to
aspartic acid using COOT [29] and the structures were energy
optimized without ATP using Phenix.
Figure 1 Multiple post-translational modiﬁcations of CaMKII are
suggested by 2D gel analysis of vascular tissue homogenates
(A) Calculated molecular mass (Mw) and pIs of CaMKII γ variants.
Vimentin (P08670) was used for comparison as a marker. (B) Repres-
entative CaMKII γ immunoblot (rabbit antibody) of a 2D gel of a whole
cell homogenate of aorta tissue. (C) Subsequent probing of blot shown
in (B) with a second rabbit antibody speciﬁc for the CaMKII γ G-2 variant
(shown with arrow) (D) Probe of same blot for vimentin (mouse antibody)
as a reference protein. (E) Merged view of CaMKII γ variants and G-2
variant (red) and vimentin (green). The brightness of the entire blot has
been uniformly altered for visual display, digital values are unchanged.
Antibodies and reagents
The antibodies used in present study were rabbit anti-
total CaMKII γ (1:250 dilution; Upstate/Millipore); rab-
bit anti-CaMKII γ G-2 [21] (1:500 dilution); mouse anti-
vimentin antibody (1:400 dilution; Sigma); mouse anti-tubulin
(1:1000 Cell Signaling); mouse anti-His-tag antibody (1:5000
dilution; Cell Signaling); rabbit anti-phosphothreonine antibody
(1:500 dilution; Cell Signaling); mouse anti-pThr287 antibody
(Millipore); rabbit anti-CaMKII G-2 (1:500 dilution) [21]; ﬂuor-
escently labelled secondary antibodies (1:1000 dilution; LI-COR
Biosciences). DMEM (Gibco), FBS (Gibco), OPTI-MEM (Invit-
rogen), protease inhibitor (Roche), QuikChange II XL (Strata-
gene), LipofectamineTM (Invitrogen), Biomol Green reagent
(Biomol International). cDNA sequences are from ferret.
Statistics
Unless indicated otherwise, signiﬁcance of difference between
two individual datasets was taken at P<0.05 by a two-tailed
paired Student’s t test. Data are presented as means+ −S.E.M.
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Figure 2 Ser280 and Ser26 autophosphorylation sites are selectively dephosphorylated by SCP3
(A)C a M K I Iγ C-1 domain structure. Red stars mark the residues previously shown to be autophosphorylated. aa, amino
acid(s). (B) Dephosphorylation of phosphopeptides with and without SCP3 measured by a colorimetric assay for free
phosphate.
RESULTS
2D gels indicate multiple post-translational
modiﬁcations of CaMKII γ in vascular tissue
To determine whether CaMKII γ variants are phosphorylated at
multiple sites in vascular tissue, we analysed vascular homogen-
ates by 2D gel electrophoresis followed by immunoblotting, us-
ing vimentin as a reference protein. Vimentin has a calculated pI
of 5.1 and post-translationally modiﬁed forms of vimentin from
human arterial smooth muscle cells are known to run within
the range 3.8–4.9 (Figure 1A) in 2D maps [30]. As shown in
Figure 1(A), the calculated pIs of CaMKII γ variants cover the
range 6.8–7.3. Figure 1(B) shows a Western blot of all CaMKII
γ variants separated by 2D gel electrophoresis and stained with
an anti-total CaMKII γ antibody. In addition to probing with the
total CaMKII γ antibody (rabbit polyclonal, red channel), we
subsequently co-labelled the blot with a CaMKII γ G-2 variant-
speciﬁc antibody (also a rabbit polyclonal, red channel) to con-
ﬁrm the identity of CaMKII spots on the 2D gel. The CaMKII
γ G-2-speciﬁc antibody typically stains an oval apparently con-
taining several forms of the G-2 variant on the blot (Figure 1C,
arrow). The same membrane was probed with an anti-vimentin
antibody (monoclonal mouse, green channel) as a reference pro-
tein (Figures 1A and 1D). Figure 1(E) shows a merged image
of total CaMKII and G-2 signals (red channel) and the vimentin
signal (green channel). Despite their expected pI of around 7.0,
CaMKII γ variants overlap with vimentin in a pI range below
5.0. Since the observed pIs for CaMKII γ variants vary from the
calculated pI by roughly 2.0, these ﬁndings suggest that CaMKII
variants are phosphorylated in aorta tissue. A single-site phos-
phorylation shifts the pI approximately 0.5 unit in the acidic
direction [31]. Thus, comparison of the calculated and observed
pI values suggests the presence of up to four to ﬁve phosphate
groups or other post-translational modiﬁcations on CaMKII in
vascular tissue.
CaMKII Ser26 and Ser280 peptides are selectively
dephosphorylated by SCP3
Previous in vitro analysis of autophosphorylation sites in the
presence of Ca2+/CaM on recombinant CaMKII γ by LC–
MS/MS of recombinant CaMKII γ identiﬁed new phosphoryla-
tion sites (Ser26,T h r 262,S e r 319 and Ser350) and conﬁrmed other
phosphorylation sites (Thr287,T h r 254 and Ser280)[ 7]. We have
also previously described SCP3 that binds CaMKII γ and de-
creases incorporated 32P, but does not dephosphorylate Thr287
[7]. However, it is not known whether any of the other iden-
tiﬁed phosphorylated site(s) are dephosphorylated by this phos-
phatase.Thus,wesynthesizedphosphopeptidescontainingallthe
..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 3 Phosphorylation of Ser26 but not Ser280 is regulated by vascular tissue depolarization
(A–D) Antibody controls, tubulin used as a loading control. (A) Whole cell aorta homogenate immunoblotted
with pCaMKIISer280 immune or preimmune serum as indicated. (B) Whole cell aorta homogenate probed with
pCaMKIISer280-speciﬁc antibody in the presence of increasing amounts of a competing pCaMKIISer280 peptide used
as the immunogen to raise the antibody. (C) Whole cell aorta homogenate immunoblotted with pCaMKIISer26 immune
or preimmune serum. (D) Whole cell aorta homogenate probed with pCaMKIISer26-speciﬁc antibody in the presence of
increasing amounts of the pCaMKIISer26 peptide used as the immunogen to raise the antibody. (E) Average densitometry
for pCaMKIISer280 staining of unstimulated tissue or that depolarized with 51 mM PSS. (F) Average densitometry for
pCaMKIISer26 staining of unstimulated tissue or that depolarized with 51 mM PSS, P<0.01 (G) Average densitometry
for pCaMKIISer287 staining of unstimulated tissue or that depolarized with 51 mM PSS. P<0.01 (H) Typical blots stained
with anti-pCaMKIISer280, pCaMKIISer26 and pCaMKIIThr287 antibodies; n=3–15. The brightness of entire blot has been
uniformly altered for visual display; digital values are unchanged.
previously identiﬁed [7,19] autophosphorylation sites: Ser26,
Thr254,T h r 262,S e r 280,T h r 287,S e r 319 and Ser350 (Figure 2A). De-
phosphorylation of these peptides by SCP3, was analysed using
a colorimetric phosphate release assay. The results (Figure 2B)
demonstrate selective dephosphorylation of only two sites, Ser26
and Ser280 by SCP3. In contrast, Thr254,T h r 262,T h r 287,S e r 319
and Ser350 were not signiﬁcantly dephosphorylated. Thus, these
ﬁndings raise the question of whether and how the phosphoryla-
tion/dephosphorylation of these sites is regulated in vivo. Thus,
we focused speciﬁcally on Ser26 and Ser280.
Phosphorylation of CaMKII at Ser280 is not
regulated by depolarization in vascular tissue
Ser280 is located within a conserved stretch of 39 residues that
constitutestheautoinhibitoryandtheCa2+/CaM-bindingdomain
inthecanonicalkinasefold.Itislocatedonlysevenresiduesaway
from Thr287, the site responsible for the autonomous activity of
CaMKII. It appears, however, to have a different function from
that of Thr287 because as shown above it is dephosphorylated by
SCP3, while Thr287 is not. To test if phosphorylation of Ser280 is
regulated in vivo, a phosphospeciﬁc Ser280 antibody was gen-
erated using the sequence H2N-RSTVAS(p)MMHRQ-COOH.
Speciﬁcity of the antibody was conﬁrmed by comparison with
preimmune serum and by probing aorta homogenate with the
pCaMKIISer280-speciﬁc antibody in the presence of competing
antigen (Figures 3A and 3B).
Vascular tissues were quick-frozen in the presence or absence
of the depolarizing stimulus (51mM KCl PSS). Depolarization
is known to open voltage-dependent Ca2+ channels in this tis-
sue, raising intracellular Ca2+ levels and activating CaMKII.
Tissue homogenates were probed by immunoblot with the anti-
pCaMKIISer280 antibody. Mean densitometry results show no
signiﬁcant difference between the unstimulated and stimulated
vascular samples (Figure 3E), suggesting that phosphorylation
of Ser280 is not regulated under these physiological conditions.
As a positive control, a pThr287-speciﬁc antibody was used to
conﬁrm CaMKII activation in these tissues (Figure 3G).
Phosphorylation of Ser26 is regulated by
depolarization in vascular tissue
Ser26 is located within a conserved stretch of nine residues
(LGKGAFSVV) that constitute the upper lid of the ATP-
binding site in the canonical kinase fold (bold letters in-
dicate conserved residues). To test the physiological import-
ance of CaMKII phosphorylation at Ser26 during vascular
depolarization, a phosphospeciﬁc antibody against Ser26 was
raised using the phosphopeptide sequence H2N-LGKGAFS(p)-
VVRRCVKKTSTQE-COOH.Antibodyspeciﬁcitywastestedby
comparing preimmune and immune serum staining of aorta ho-
mogenates.Asignalattheexpectedmolecularmasswasdetected
only with immune serum (Figure 3C). The identity of the band
was conﬁrmed with a pCaMKIIThr287-speciﬁc antibody (results
not shown). Next, the phosphopeptide used to raise the antibody
was mixed with the antibody in a competition assay. As shown in
Figure3(D),thecompetingpeptidedecreasedtheantibodysignal
in a concentration-dependent manner.
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Figure 4 Phosphomimic mutation of Ser26 decreases Thr287 autophosphorylation and leads to an impaired catalytic
activity toward exogenous Thr287 substrate peptide
(A) Lysates from His-tagged C-1 wt, C-1 S26D or C-1 S26A or mock-transfected (NT) COS-7 cells probed with the indicated
antibodies. (B) Densitometric quantiﬁcation of the results of three similar experiments. ***P0.0001. (C) CaMKII wt,
CaMKII S26D and CaMKII S26A recombinant proteins mixed with autocamtide-3 in a kinase activating buffer and dotted
on membrane and probed for phosphothreonine. Peptide and kinase were separated using a sizing spin column and the
peptide fraction used for dot blot. (D) Quantiﬁcation of the results from ﬁve similar experiments. The results are normalized
by the amount of kinase used in each assay. ***P0.001. The brightness of entire blot has been uniformly altered for
visual display; digital values are unchanged.
Next, we tested CaMKII phosphorylation at Ser26 during
vascular depolarization. The level of Ser26 phosphorylation on
CaMKIIwascomparedbetweenunstimulatedversusdepolarized
quick-frozen vascular tissue homogenates. As is shown in Fig-
ure3(F),densitometricanalysisofthephospho-Ser26 immuoblots
normalized to tubulin co-staining shows a signiﬁcant increase
(∼50%) with depolarization for 10 min with KCl PSS. Thus,
phosphorylation of Ser26 on CaMKII is regulated during contrac-
tion in vascular tissue.
A phosphomimic S26D mutation inhibits Thr287
autophosphorylation of CaMKII
We postulated that Ser26 phosphorylation of CaMKII might al-
ter kinase activity. To test this hypothesis, we determined the
effect of mutation of Ser26 to alanine (A) or as-
partic acid (D) in recombinant CaMKII. Kinase activity was
assayed by monitoring Thr287 autophosphorylation. COS-7 cells
were transfected with CaMKII wt, the S26D mutant or the S26A
mutant. The COS-7 cell line used has no endogenous detectable
CaMKII protein expression (Figure 4A). Therefore the CaMKII
holoenzyme in the transfected COS-7 cells is a homo-oligomer.
The Thr287 phosphorylation level was measured by probing the
transfected COS-7 cell lysates in immunoblots. The results were
normalized for transfection efﬁciency by probing co-stained im-
munoblots with an anti-total CaMKII γ antibody (Figure 4A).
Densitometric analysis of the normalized Thr287 phosphorylation
levels of the S26D and S26A mutants and wt CaMKII indicates
that the level of Thr287 phosphorylation is markedly reduced in
theS26Dmutant(∼80%)(Figure4B).Thr287 phosphorylationof
wtandS26Awerenotsigniﬁcantlydifferent.Theseresultsindic-
ate that phosphorylation of Ser26 inhibits Thr287 phosphorylation
in the CaMKII γ homo-oligomer while the S26A mutation has
no effect.
The phosphomimic CaMKII S26D mutant cannot
phosphorylate exogenous CaMKII Thr287 substrate
To investigate whether the observed inhibition of Thr287 phos-
phorylation in the S26D mutant is due to a direct inhibition
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of kinase activity, an in vitro kinase assay was performed us-
ing a 13-amino-acid peptide containing Thr287 (autocamtide-3)
as a substrate. His-tagged puriﬁed recombinant CaMKII wt, the
S26D mutant and the S26A mutant were used in vitro dot-blot
kinase assays containing 20 μM autocamtide-3, 5 μg/ml CaM
and 10 mM CaCl2 to activate the kinase. The phosphorylated
peptide was separated from the holoenzyme (∼680 kDa) using a
sizing spin column. As shown in Figure 4(C) and is quantiﬁed in
Figure 4(D), the S26D mutant caused negligible threonine phos-
phorylation of the exogenous peptide even though signiﬁcant
amounts of peptide phosphorylation were seen with the S26A
mutant and wt kinase. The S26A mutant showed signiﬁcantly
more activity in phosphorylating the substrate peptide than did
wt kinase, suggesting that autophosphorylation of the wt kinase
leads to less than the maximal possible kinase activity.
Taken together, these results indicate that the negative charge
on Ser26 of CaMKII γ introduced by the mutation or by auto-
phosphorylation of wt kinase inhibits the catalytic activity of the
enzyme towards its autophosphorylation site at Thr287.
Structural interpretation of the CaMKII inhibition by
Ser26 phosphorylation
In the absence of a three-dimensional structure of CaMKII phos-
phorylated on Ser26 we used homology modelling to explain a
plausible mechanism for the kinase inhibition by Ser26 phos-
phorylation or S26D mutation. Ser26 is located in a stretch of
residues that form the ﬁrst two β-strands and the connecting
loop of the β domain in the canonical kinase fold. We refer
to this segment as the ‘upper lid’ of the ATP-binding site be-
cause these residues make extensive interactions with the ATP
molecule, speciﬁcally with the triphosphate moiety, as observed,
for example, in the structure of the PKA–ATP complex [32].
Glycine is the most commonly found amino acid at the position
corresponding to CaMKII Ser26. This semi-conserved glycine
residue plays an important role in positioning the triphosphate
moiety for catalysis by making a strong hydrogen bond with
one of the β-phosphate oxygen atoms. Besides the serine
residue found in all CaMKII isoforms there are also alanine and
histidine found among the very few substitutions at this pos-
ition in the kinase superfamily. Thus, there must be a strong
evolutionary selection at this position and it is probable that the
glycine→serinesubstitutionplaysanimportantfunctionspeciﬁc
for CaMKII. To evaluate the possible consequences of introdu-
cing an acidic group at this position, we have modelled the wt
CaMKII γ C-1 isoform, its phosphorylated form and the S26D
mutant based on the structure of PKA (PDB entry 1ATP). We
found the PKA structure to be a better template for the model-
ling than the recently published structure of CaMKII γ isoform
(PDB entry 1V7O), because in the latter the loop containing
Ser26 is disordered due to the absence of the triphosphate moiety
in the bound inhibitor. In the modelled structure of C-1, all the
interactions between the protein and ATP are well preserved in-
cluding a correct geometry and bond lengths for the bound metal
(Mn2+),whichpositionstheγ phosphateforcatalysis.Therefore
we are conﬁdent that our model has all the essential features of
Figure 5 Atomic model depicting a role for Ser26 phosphorylation
(A) Alignment with the protein whose structure was used for modelling
and marking the residues that were used for structural homology align-
ment residues involved in ATP binding are shown in red (B) On the left,
the front and the back view (rotated 180◦ on the y-axis) of the modelled
C-1 wt structure with ATP . On the right, close view of atomic structure of
unphosphorylated Ser26, S26D and phosphorylated Ser26 (Ser26-PO4)
on modelled CaMKII C-1 structure with ATP . Atomic colour code: Phos-
phate (orange), oxygen (red), carbon (green), nitrogen (blue). Structures
drawn using the PyMOL Molecular Graphics System, version 1.2r3pre,
Schr¨ odinger.
the CaMKII structure. The modelled structures suggest that the
negatively charged side chain carboxy group of the aspartic acid
residue or the phosphate attached to the serine side chain oxy-
gen would clash with the β-phosphate group of ATP, thus either
sterically interfering with the catalysis, i.e. with the transfer of
the γ phosphate to a substrate such as Thr287 or inhibiting the
ATP binding (Figure 5). Furthermore, owing to the orientation of
the Ser26 side chain towards the catalytic cleft, and its position
close to the β-phosphate of the bound ATP, this side chain is
not readily accessible to an external kinase molecule. It appears
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Figure 6 Conservation of Ser26 across species
Homo sapiens CaMKII γ isoform 1 (NP_751911.1), Mus musculus CaMKII γ isoform 1 (NP_848712.2), Mustela putorius
furo (AAL69953.1), Rattus norvegicus CaMKII γ (NP_598289.1), Xenopus laevis CaMKII γ M (AAG17558.1), Drosophila
melanogaster CaMKII isoform B (AAF59390.2)
that the phosphorylation of Ser26 most probably occurs by an
intramolecular mechanism. We propose that phosphorylation of
Ser26 works as an internal break that allows the switching off the
constitutively active oligomeric CaMKII.
DISCUSSION
CaMKII Ser26 is conserved in all CaMKII isoforms from mam-
mals through to Drosophila, but not in yeast (Figure 6). This
points to an important functional role for the site. Additionally,
Ser26 is known to be part of the ATP-binding motif of the cata-
lytic domain [33]a ss h o w ni nFigure 5(A). In the current study,
we have demonstrated, ﬁrst, that Ser26 in CaMKII γ is regulated
by phosphorylation during depolarizing stimuli in blood vessels
and, secondly, by mutagenesis that phosphorylation at this site
switchesoffCa2+-activatedkinaseactivity,preventingprolonged
kinase activity.
Ser26 is located within a conserved stretch of nine residues
(LGKGAFSVV)thatconstitutestheupperlidoftheATP-binding
site in the canonical kinase fold. The phosphomimic mutation
of CaMKII (S26D) causes a dramatic decrease in Thr287 phos-
phorylation levels, while the S26A mutation has no effect. The
decreased Thr287 autophosphorylation in the oligomer could be
due to a number of possible mechanisms. To directly test the
possibility that the Ser26 phosphomimic impairs the activity of
the catalytic cleft, we used an exogenous substrate known as
autocamtide-3, and found, indeed that the phosphomimic kinase
(S26D) has an impaired catalytic activity.
One interesting issue that arises is that, when whole vascular
tissue homogenates are probed in immunoblots for phosphoryla-
tionofCaMKIIThr287 andSer26 phosphorylation(Figure3)phos-
phorylation of both sites appears to coexist during steady-state
depolarization of the tissue. This is in marked contrast with the
results with the phosphomimic mutants in recombinant homo-
oligomers(Figure4).Tissue-widedepolarizationofcellsleadsto
a non-selective Ca2+ rise in stimulated VSMCs, which is expec-
ted to globally activate a large pool of CaMKII. Global activation
of a promiscuous kinase is unlikely to be advantageous to the cell
and would be expected to disrupt targeting of speciﬁc signalling
pathways. Thus, Ser26 phosphorylation might be a mechanism
controlling the spatially distributed CaMKII activity during a
rapid Ca2+ ﬂ u xi n t ot h eV S M C s .
CaMKII in which either Ser26 or Thr287 is phosphorylated
may occur in different cellular pools. This concept is consist-
ent with what we know about the targeting of the G-2 variant
of CaMKII γ in smooth muscle and its interaction with SCP3.
SCP3 is a small PP2C (protein phophatase 2C)-type C-terminal
domainphosphatasepresentinvascular smoothmuscle.CaMKII
γ G-2 and SCP3 are co-localized on a central vimentin- and α
actinin-containing cytoskeleton in unstimulated VSMCs; how-
ever, once the cell is depolarized G-2 and SCP3 separate and
G-2 is targeted to the cell surface [21]. SCP3 is of interest since
it decreases total 32P incorporation into CaMKII by autophos-
phorylation but does not dephosphorylate Thr287 [7]. We now
show that it dephosphorylates Ser26 and Ser280 preferentially,
with no activity towards other sites including Thr287 (Figure 3).
Thus, when CaMKII and SCP3 co-localize, SCP3 would keep
Ser26 dephosphorylated but when they separate, Ser26 would be
phosphorylated by the still active kinase and would then inhibit
kinase activity, producing a ‘sleeping’ pool of CaMKII at the cell
surface.
We have previously reported that the B and J variants of the
CaMKII γ isoform ‘autodephosphorylate’ [19]. Others have de-
scribed a similar phenomenon and attributed it to a reverse of
the activation mechanism [34], but this mechanism did not fully
explain our observations. The effect of Ser26 phosphorylation to
inhibit kinase activity could well explain these previous observa-
tions as well. Thus, if Thr287 phosphorylation is a mechanism for
‘remembering’phosphorylation[35],thenSer26 phosphorylation
may be a mechanism for ‘forgetting’.
Taken together, we demonstrate here that there are novel auto-
phosphorylationsinvitroandinvivoonCaMKII,andSer26 isone
ofthem.W eha v edisco v eredthataSer 26 phosphomimicCaMKII
has impaired Thr287 phosphorylation and reduced catalytic activ-
ity, probably due to inhibition of ATP binding. This action con-
stitutes an important mechanism for switching the kinase off,
possibly in a spatially targeted manner.
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